Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study
Brady L. Stein(Barnes-Jewish Hospital), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Shreekant Parasuraman(Incyte (United States)), Michael R. Grunwald(Levine Cancer Institute), Alison R. Moliterno(Johns Hopkins University), Joseph A. Cordaro(Incyte (United States)), Dilan Paranagama(Incyte (United States)), Ahmad Naim(Incyte (United States)), Stephen T. Oh(Washington University in St. Louis), Ralph V. Boccia(Center for Cancer and Blood Disorders), Haowei Sun(University of Alberta)
Cited by 2
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
|Science Translational Medicine|2016|916
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761